Craig-Hallum analyst Alexander Nowak lowered the firm’s price target on Sientra to $10 from $13 and keeps a Buy rating on the shares. Sientra’s Q4 results were slightly below the Street, but the company gave a bullish update on the business and strong guidance to back it up, the analyst tells investors in a research note. Management expects to be cash flow breakeven exiting 2023, which is likely ahead of investor expectations but there will likely be skepticism given previous breakeven comments, the firm says.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SIEN:
- Sientra Reports Record Fourth Quarter and Full Year Revenues and Expands Total Addressable Market With New Product Launches
- Sientra (SIEN) Q4 Earnings Cheat Sheet
- Aziyo Biologics, Sientra team on SimpliDerm for soft tissue reconstruction
- Sientra to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
- Sientra Announces Preliminary Results from Clinical Study and The First Shipment of Viality™ Fat Transfer System